{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:40:00Z","timestamp":1792604400879,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01065-0","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:00:52Z","timestamp":1792602052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical Advances and Evidence-Proportionate Biosimilar Development"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6778-7114","authenticated-orcid":false,"given":"Ryosuke","family":"Kuribayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miya","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanoko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"6","key":"1065_CR1","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40259-023-00631-4","volume":"37","author":"N Kirsch-Stefan","year":"2023","unstructured":"Kirsch-Stefan N, Guillen E, Ekman N, Barry S, Knippel V, Killalea S, Weise M, Wolff-Holz E. Do the outcomes of clinical efficacy trials matter in regulatory decision-making for biosimilars? BioDrugs. 2023;37(6):855\u201371.","journal-title":"BioDrugs"},{"key":"1065_CR2","unstructured":"IPRP Biosimilars Working Group. Workshop summary report: increasing the efficiency of biosimilar development programs\u2014reevaluating the need for comparative clinical efficacy studies. 2024 https:\/\/admin.iprp.global\/sites\/default\/files\/2024-07\/IPRP_BWG_Final%20IPRP%20Scientific%20Workshop%20Summary%20Report_2024_0506.pdf. Accessed 5 Oct 2026."},{"key":"1065_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40290-025-00583-w","volume":"39","author":"K Goto","year":"2025","unstructured":"Goto K, Hariu A, Kuribayashi R. Survey on the role of comparative efficacy studies required for biosimilar monoclonal antibody approval in Japan to justify the quality attribute differences between biosimilars and their reference products based on the pharmaceuticals and medical devices agency (PMDA) assessments. Pharm Med. 2025;39:477\u201391.","journal-title":"Pharm Med"},{"key":"1065_CR4","unstructured":"IQVIA. Assessing the biosimilar void in the U.S. 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/assessing-the-biosimilar-void-in-the-us.\u00a0Accessed 28 May 2026."},{"key":"1065_CR5","doi-asserted-by":"publisher","first-page":"832059","DOI":"10.3389\/fbioe.2022.832059","volume":"10","author":"N Nupur","year":"2022","unstructured":"Nupur N, Joshi S, Gulliarme D, Rathore AS. Analytical similarity assessment of biosimilars: global regulatory landscape, recent studies and major advancements in orthogonal platforms. Front Bioeng Biotechnol. 2022;10:832059.","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"1065_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nrd3746","volume":"11","author":"SA Berkowitz","year":"2012","unstructured":"Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1065_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12248-026-01206-1","volume":"28","author":"AS Rathore","year":"2026","unstructured":"Rathore AS, Suryanarayanan R, Nejadnik R, Gurvich VJ, Singh SK, Sarin D. Best practices for performing analytical and functional biosimilarity assessment of recombinant monoclonal antibody biosimilars. AAPS J. 2026;28(2):62.","journal-title":"AAPS J"},{"issue":"4","key":"1065_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40259-026-00786-w","volume":"40","author":"R Aithal","year":"2026","unstructured":"Aithal R, Majedi OM, McCarthy D, Atouf F, Peckham N. Review of Quality attributes and analytical methods used for comparative analytical assessment of monoclonal antibodies as part of successful biosimilar approvals in the United States and European Union. BioDrugs. 2026;40(4):713\u201332.","journal-title":"BioDrugs"},{"key":"1065_CR9","unstructured":"U.S. FDA. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. 2025. https:\/\/www.fda.gov\/media\/159261\/download.\u00a0Accessed October 5, 2026."},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.tibtech.2023.08.008","volume":"42","author":"AS Rathore","year":"2024","unstructured":"Rathore AS, Sarin D. What should next-generation analytical platforms for biopharmaceutical production look like? Trends Biotechnol. 2024;42:282\u201392.","journal-title":"Trends Biotechnol"},{"key":"1065_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3390\/ph19050745","volume":"19","author":"V Duarte","year":"2026","unstructured":"Duarte V, Bas TG. Advances in biosimilars: a systematic review of machine learning applications. Pharmaceuticals. 2026;19:745.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"1065_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40259-020-00422-1","volume":"34","author":"M Schiestl","year":"2020","unstructured":"Schiestl M, Ranganna G, Watson K, Jung B, Roth K, Capsius B, Trieb M, Bias P, Mar\u00e9chal-Jamil J. The path towards a tailored clinical biosimilar development. BioDrugs. 2020;34(3):297\u2013306.","journal-title":"BioDrugs"},{"issue":"5","key":"1065_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40259-023-00619-0","volume":"37","author":"HP Cohen","year":"2023","unstructured":"Cohen HP, Turner M, McCabe D, Woollett GR. Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer\u2019s Perspective. BioDrugs. 2023;37(5):583\u201393.","journal-title":"BioDrugs"},{"issue":"5","key":"1065_CR14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40259-025-00733-1","volume":"39","author":"M Schiestl","year":"2025","unstructured":"Schiestl M, Roy N, Trieb M, Park JP, Guillen E, Woollett G, Wolff-Holz E. Analytical data and single-dose PK are sufficient to conclude comparable immunogenicity for biosimilars: an ustekinumab case study. BioDrugs. 2025;39(5):769\u201376.","journal-title":"BioDrugs"},{"key":"1065_CR15","unstructured":"MHLW. Questions and Answers (Q&A) on guideline for ensuring the quality, safety, and efficacy of biosimilars. 2024. https:\/\/www.pmda.go.jp\/files\/000267480.pdf.\u00a0Accessed 25 April 2026."},{"key":"1065_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1080\/14712598.2024.2377300","volume":"24","author":"R Kuribayashi","year":"2024","unstructured":"Kuribayashi R, Goto K, Hariu A, Kishioka Y. Revisions to the requirement of the Japanese clinical study data for biosimilar developments in Japan. Expert Opin Biol Ther. 2024;24:637\u201345.","journal-title":"Expert Opin Biol Ther"},{"key":"1065_CR17","unstructured":"PMDA. Early Consideration on handling of Japanese data for confirmation of comparability of biosimilars to the original biopharmaceuticals. 2025. https:\/\/www.pmda.go.jp\/files\/000277274.pdf.\u00a0Accessed 11 July 2026."},{"key":"1065_CR18","unstructured":"MHLW. Questions and answers (Q&A) on guideline for ensuring the quality, safety, and efficacy of biosimilars (Part 2). 2026. https:\/\/www.pmda.go.jp\/files\/000280738.pdf.\u00a0Accessed 21 May 2026."},{"key":"1065_CR19","unstructured":"PMDA Considerations for determining the necessity of comparative efficacy studies in demonstrating biosimilarity between biosimilars and reference products (early consideration). 2026. https:\/\/www.pmda.go.jp\/files\/000280747.pdf.\u00a0Accessed 21 May 2026."},{"key":"1065_CR20","unstructured":"U.S. FDA. Scientific considerations in demonstrating biosimilarity to a reference product: updated recommendations for assessing the need for comparative efficacy studies (draft guidance). 2025. https:\/\/www.fda.gov\/media\/189366\/download.\u00a0Accessed 24 April 2026."},{"key":"1065_CR21","unstructured":"EMA. Reflection paper on a tailored clinical approach in biosimilar development. 2026 https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf-0. Accessed 24 April 2026."},{"key":"1065_CR22","unstructured":"ICH M18 Final Concept Paper. Framework for determining the utility of comparative efficacy studies in biosimilar development programs. 2025 https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf. Accessed 28 May 2026."},{"key":"1065_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2785","volume":"113","author":"E Guillen","year":"2023","unstructured":"Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113:108\u201323.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1065_CR24","first-page":"601","volume":"85","author":"E Guillen","year":"2025","unstructured":"Guillen E, Barry S, Jost N, Ekman N, Knippel V, Kuhlmann-Gottke J, Maier J, Weise M, Laslop A, Anour R, van Zandbergen G, Kirsch-Stefan N. Tailored biosimilar approach: expect requirements drugs. 2025;85(5):601\u20138.","journal-title":"Tailored Biosimilar Approach: Expect Requirements Drugs"},{"key":"1065_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/cpt.2761","volume":"113","author":"DG Strauss","year":"2023","unstructured":"Strauss DG, Wang YM, Florian J, Zineh I. Pharmacodynamic biomarkers evidentiary considerations for biosimilar development and approval. Clin Pharmacol Ther. 2023;113:55\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"1065_CR26","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/cpt.2795","volume":"113","author":"J Florian","year":"2023","unstructured":"Florian J, Sun Q, Schrieber SJ, White R, Shubow S, Johnson-Williams BE, Sheikhy M, Harrison NR, Parker VJ, Wang YM, Strauss DG. Pharmacodynamic biomarkers for biosimilar development and approval: a workshop summary. Clin Pharmacol Ther. 2023;113:1030\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"1065_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40259-025-00722-4","volume":"39","author":"H Shibata","year":"2025","unstructured":"Shibata H, Harazono A, Kiyoshi M, Saito Y, Ishii-Watabe A. Characterization of biosimilar monoclonal antibodies and their reference products approved in Japan to reveal the quality characteristics in post-approval phase. BioDrugs. 2025;39:645\u201367.","journal-title":"BioDrugs"},{"key":"1065_CR28","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1007\/s40265-021-01601-2","volume":"81","author":"P Kurki","year":"2021","unstructured":"Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E, Safety. Immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81:1881\u201396.","journal-title":"Drugs"},{"key":"1065_CR29","unstructured":"Health Canada. Guidance on information and submission requirements for biosimilar biologic drugs. 2026 https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs\/information-submission-requirements-biosimilar-biologic-drugs.pdf. Accessed 5 Oct 2026."},{"key":"1065_CR30","unstructured":"IPRP Biosimilars Working Group. Regulatory perspectives on the utility of comparative efficacy studies in biosimilar development programs. 2026 https:\/\/admin.iprp.global\/sites\/default\/files\/files\/2026-02\/IPRP_BWG_Reg_Perspectives_CES_2026_0220.pdf. Accessed 5 Oct 2026."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01065-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:00:54Z","timestamp":1792602054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":30,"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01065-0","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"7 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}